Diabetic Kidney Disease: Early Detection and Treatment
Learn about diabetic kidney disease (DKD). Discover how to detect kidney problems early, interpret eGFR and albuminuria, and protect your kidney health with diabetes.
W
WellAlly Content Team
2025-01-11
•
Verified 2025-12-20
•
7 min read
Key Takeaways
20-40% of people with diabetes develop diabetic kidney disease
DKD is the #1 cause of end-stage kidney disease requiring dialysis
Screen with eGFR and urine albumin-to-creatinine ratio annually
Kidney damage can be silent—significant damage may occur before symptoms
Early detection and treatment can often slow or prevent progression
”
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or qualified health provider with any questions you may have regarding a medical condition.
Diabetic kidney disease (DKD) is a common and serious complication of diabetes. It's the leading cause of end-stage kidney disease requiring dialysis or transplant.
The scary part? Kidney damage can be silent for years. You may not notice symptoms until significant damage has occurred.
The good news: with early detection and proper treatment, diabetic kidney disease can often be slowed or prevented. The 2025 ADA guidelines provide a clear roadmap for protecting your kidneys.
What Is Diabetic Kidney Disease?
How Diabetes Damages Kidneys
Process
Effect
High blood glucose
Damages filtering units (glomeruli)
High blood pressure
Increases pressure in kidney filters
Inflammation
Causes scarring of kidney tissue
Fibrosis
Progressive loss of functional tissue
Albumin leakage
Protein spills into urine
Why It Matters
Statistic
Impact
20-40% of people with diabetes develop DKD
#1 cause of ESRD in the US
Increases mortality 2-3x compared to diabetes without DKD
Silent progression until advanced stages
Screening: 2025 ADA Recommendations
Who Should Be Screened?
Patient Group
When to Start
Type 1 diabetes
5 years after diagnosis
Type 2 diabetes
At diagnosis
Both types
Annually thereafter
What Tests Are Needed?
Test
What It Measures
Target
eGFR
Estimated glomerular filtration rate
≥ 60 mL/min/1.73 m²
UACR
Urine albumin-to-creatinine ratio
＜ 30 mg/g
Understanding Your Kidney Tests
eGFR (Kidney Function)
Category
eGFR (mL/min/1.73 m²)
Meaning
G1
≥ 90
Normal or high
G2
60-89
Mildly decreased
G3a
45-59
Mild-moderate decrease
G3b
30-44
Moderate-severe decrease
G4
15-29
Severely decreased
G5
＜ 15
Kidney failure
UACR (Albumin in Urine)
Category
UACR (mg/g)
Meaning
A1
＜ 30
Normal to mildly increased
A2
30-300
Moderately increased (microalbuminuria)
A3
> 300
Severely increased (macroalbuminuria)
CKD Staging (Combining eGFR and Albuminuria)
Stage
eGFR
Albuminuria
Risk
Stage 1
≥ 90
A1-A3
Low-moderate
Stage 2
60-89
A1-A3
Low-moderate
Stage 3a
45-59
A1-A3
Moderate-high
Stage 3b
30-44
A1-A3
High
Stage 4
15-29
A1-A3
Very high
Stage 5
＜ 15
A1-A3
Very high
Treatment: Protecting Your Kidneys
Glycemic Control
Target
Benefit
A1C ＜ 7.0% (individualized)
Slows DKD progression by 30-50%
Early control
Greatest benefit before significant damage
Avoid hypoglycemia
Especially in advanced CKD
Note: Once advanced CKD develops, A1C targets may be relaxed to avoid hypoglycemia.
Blood Pressure Control
Target
Population
<130/80 mmHg
Most patients with diabetes + albuminuria
<140/90 mmHg
Older adults or frail patients
First-Line Medications
Medication Class
Kidney Benefit
Notes
ACE inhibitors
Slows DKD progression
First choice
ARBs
Slows DKD progression
Alternative if ACE not tolerated
Combination
NOT recommended
Increases risk
Key point: Most people with diabetes + albuminuria should be on an ACE inhibitor or ARB regardless of blood pressure.
SGLT2 Inhibitors
Medication
Kidney Benefit
When to Use
Canagliflozin
Slows eGFR decline, reduces ESRD
eGFR ≥ 20
Dapagliflozin
Slows eGFR decline, reduces ESRD
eGFR ≥ 25
Empagliflozin
Cardio-renal benefit
eGFR ≥ 20
Ertugliflozin
Similar benefits
eGFR ≥ 30
Evidence: CREDENCE, DAPA-CKD, and EMPA-KIDNEY trials showed SGLT2 inhibitors slow DKD progression by 30-40%.
Non-Steroidal MRA
Medication
Benefit
When to Use
Finerenone
Reduces albuminuria, slows eGFR decline
Type 2 diabetes + CKD (eGFR 25-90)
Note: Monitor potassium levels when using finerenone.
GLP-1 Receptor Agonists
Benefit
Evidence
Reduced albuminuria
Consistent across agents
Slowed eGFR decline
Some agents
Cardiovascular benefit
Proven for several agents
Nutrition Considerations
Protein Intake
Patient Category
Recommended Protein Intake
DKD stages 1-4
0.8 g/kg body weight/day
Dialysis
1.0-1.2 g/kg body weight/day
Note: High protein intake may increase kidney hyperfiltration and accelerate damage.
Annual screening for DKD is essential for all people with diabetes
Type 2: screen at diagnosis; Type 1: screen 5 years after diagnosis
Two tests needed: eGFR (kidney function) and UACR (albumin in urine)
ACE inhibitors or ARBs are first-line for diabetes + albuminuria
SGLT2 inhibitors provide additional kidney protection
Blood pressure target: ＜ 130/80 mmHg for most patients
Refer to nephrology when eGFR ＜ 30 or rapid decline
FAQ Section
What are the early signs of kidney disease in diabetes?
Early diabetic kidney disease typically has NO symptoms. As kidney function declines, you may notice swelling in legs/feet/eyes, increased fatigue, foamy urine, or needing to urinate more at night. This is why annual screening with blood and urine tests is essential—don't wait for symptoms.
What eGFR level requires seeing a kidney specialist?
An eGFR below 30 mL/min/1.73 m² generally warrants referral to a nephrologist (kidney specialist). Earlier referral may be appropriate if there's rapid decline in kidney function, difficult-to-control blood pressure, or uncertainty about the cause of kidney disease.
Can diabetic kidney disease be reversed?
Once significant kidney damage has occurred, it generally cannot be reversed. However, progression can often be slowed or even halted with proper management including tight glycemic control, blood pressure control, and kidney-protective medications (ACE inhibitors/ARBs, SGLT2 inhibitors).
What foods should be avoided with diabetic kidney disease?
With diabetic kidney disease, limit high-sodium foods (＜ 2,000 mg/day), limit protein to 0.8 g/kg/day (unless on dialysis), and in advanced stages, limit potassium and phosphorus. Avoid processed foods, which are often high in sodium and phosphorus additives. Work with a renal dietitian for personalized guidance.
Do all people with diabetes need SGLT2 inhibitors for kidney protection?
Not all, but SGLT2 inhibitors are recommended for most people with type 2 diabetes and chronic kidney disease (eGFR ≥ 20-25 depending on the specific medication) because of their proven kidney and cardiovascular benefits. The decision should be individualized based on eGFR, cardiovascular risk, and other factors.
Sources:
American Diabetes Association. Standards of Care in Diabetes—2025. Diabetes Care 2025; 48(Suppl 1): S211-S225 (Section 16: Kidney Disease)
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Disclaimer: This content is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment.
#
Article Tags
diabetic kidney disease
diabetes nephropathy
eGFR
albuminuria
kidney protection
Related Medical Knowledge
Learn more about related medical concepts and tests
